Tumor Treating Fields Mesothelioma
Tumor treating fields mesothelioma is a new type of therapy that uses alternating electric fields to limit cancer growth. It is combined with chemotherapy to treat mesothelioma pleural.
Following the success of the STELLAR study, the FDA approved TTFields together with pemetrexed cisplatin. In in the year 2019. FDA approved TTFields. Patients can ask their specialist for this treatment.
Disrupting Cell Division
TTFields use alternation of electrical fields to destroy cancer cell proteins and block their cells from growing. This prevents mesothelioma tumor cells from growing or spreading to other organs within the body. The TTFields also help to increase the production of proteins that eliminate cancer cells and aid the immune system fight mesothelioma tumors.
During treatment patients wear an insulated device that is small in size. pads that adhere to the skin. The device delivers low-intensity electric current, and patients are able to decide the extent of treatment they receive. A mesothelioma treatment lasts around 30 minutes. Patients can have TTFields treatment at various times throughout the day.
A TTFields study from 2021 found that electrical fields of between 100 and 300 kilohertz were able to stop cancer cell division and cause them to die. malignant mesothelioma treatment options examined different kinds of cancerous cells, and discovered that electrical fields killed all of them, regardless of the cellular structure.
The study’s author suggested the use of TTFields and chemotherapy for mesothelioma. FDA approved Novocure’s TTFields NovoTTF 100L in 2019 to treat unresectable mesothelioma of the pleural. It is now available through mesothelioma physicians at certified medical centers across the U.S., including the West Cancer Center in Memphis. The NovoTTF 100L device, also referred to as Optune Lua has been used to treat mesothelioma when it is combined with platinum-based chemotherapy and pemetrexed. Mesothelioma victims have reported an extended survival time when the TTFields treatment has been combined with chemotherapy.
Another study, published in « Lung Cancer », reported that TTFields therapy is highly effective in conjunction with chemotherapy. Researchers discovered that combing chemotherapy with TTFields significantly reduced the number mesothelioma cancerous cells in animal models. The study also revealed that combining these treatments increased the production proteins that kill mesothelioma cancerous cells and reduce the amount or cancerous DNA found in your body.
The TTFields treatment is a relatively new treatment and many mesothelioma specialists do not provide it for pleural malignant mesothelioma. Patients still have access to this treatment through clinical trials or at mesothelioma clinics certified by Novocure.
Stalling Tumor Development
Mesothelioma forms when mesothelial cells alter and exceed their normal lifespan, resulting in an overabundance of cancerous cells that multiply and spread throughout the body. The treatment of mesothelioma fields stops tumors from advancing and spreading by preventing mesothelial cells from duplicating.
The TTFields device is worn on the chest similar to an armband and generates an array of electrical fields that can alter proteins that kill cancer cells and slow down the growth of tumors. The device is equipped with insulated pads that stick to the skin. Patients or health professionals can apply the pads at home.
Doctors recommend the combination of TTFields therapy with chemotherapy for the most effective results. The combination boosts the production of proteins that kill cancer cells and decreases the ability of cancer cells to repair DNA damage caused by chemotherapy drugs. This allows the chemotherapies work even harder and improves survival rates in mesothelioma.
In the recent STELLAR trial, a combination of TTFields therapy and chemotherapy significantly increased survival for mesothelioma sufferers. The FDA approved the NovoTTF 100L System and is now marketed as Optune Lua, for use in conjunction with pemetrexed and cisplatin or carboplatin as first-line treatment for unresectable malignant mesothelioma of the pleural in 2019.
Researchers have discovered that TTFields therapy is effective against mesothelioma by interrupting cell division. The TTFields therapy causes cancer cells to break up during a process known as mitosis. The cellular debris then is absorbed by surrounding tissues and hinders the growth of the new tissue. Mitosis also stops mesothelioma cancer cells from healing damaged DNA, and makes cells more sensitive to radiation treatment.
The TTFields therapy also helps to reduce the flow of blood to tumors through the suppression of vascular-endothelial-growth factor (VEGF) and the growth of hypoxia-inducible factors-1 alpha or HIF-1a. HIF-1a has been linked to cancer cells angiogenesis.
Consult your physician if you have been diagnosed mesothelioma. Novocure and mesothelioma experts are working together on clinical trials to evaluate the efficacy of TTFields. Contact an Novocure certified specialist at one of the more than 1,300 U.S. Treatment Centers to learn more about mesothelioma treatments using TTFields.
Killing Tumor Cells
Tumor treating fields (TTFields) disrupt cell division by sending electrical waves through the body to kill tumor cells. They are low-intensity and medium frequency electric fields that alternately target cancerous cells without harming healthy ones. The electric fields hinder DNA repair and increase cell defences, making cancerous cells more difficult to survive. TTF is non-invasive and causes only minor adverse effects.
Scientists think TTFields function by disrupting mitosis, a process by which the cell divides into two identical cells. Normal cells have controls to limit the rate of mitosis. However cancerous tumors of malignancy are able to break these limitations and multiply at a rapid rate. TTFields interfere with this process by blocking signals that control the mitosis of mesothelioma cancer cells. In the STELLAR study, TTFields when combined with chemotherapy increased survival rates for mesothelioma. Mesothelioma patients who received TTFields in addition to maintenance cycles of chemotherapy were able to live on average six months longer than patients receiving chemotherapy only.
A separate research study also found that TTFields could boost the effectiveness of certain chemotherapy drugs known as platinum-based therapies. These platinum-based therapies destroy mesothelioma by targeting mitochondria. This is where the energy for cancerous cells originates. When TTFields are utilized in conjunction with these chemotherapy drugs, the combination could result in higher levels of DNA damage and more rapid death of cancer cells.
TTFields can also enhance the effects of radiation therapy in some instances. Researchers have discovered that combining TTFields with radiation therapy could cause an « synergistic effect. » This means that the combination of treatments increases the sensitivity of mesothelioma cancer cells to radiation.
Currently, TTFields is only available in specific mesothelioma centers. A mesothelioma expert will determine if you’re suitable for this treatment. If you qualify mesothelioma lawyers can assist you in obtaining treatment that includes TTFields with chemotherapy. If you are a veteran mesothelioma lawyer could help you access treatment that is covered under your VA health benefits.
Side Effects
The TT fields therapy destroys cancer cells by creating a field of electricity that interferes with their ability to divide. This can slow the growth of tumors and prevent the spread of cancer to other areas of the body. The TT fields device is noninvasive, which means it doesn’t harm the surrounding tissue or cause pain. This is different than conventional chemotherapy, which requires intravenous injections or radiation both of which can have severe side effects.
In the study that included patients who received a combination of TT fields and temozolomide saw improvement in survival that was comparable to those who were treated with chemo on their own. Doctors attributing this improvement in survival to TT fields, which increase the efficacy of chemotherapy while reducing side adverse effects.
Mesothelioma cells can mutate into cancerous cells and reproduce uncontrollably, forming tumors that infiltrate the organs of your body. Mesothelioma treatments like TT fields prevent mesothelioma from reproducing and limiting the body’s normal functions by stopping cell division.
During a mesothelioma trial, mesothelioma patients who received TT fields in conjunction with their chemo had an average survival of 18.2 months. Those who received TT fields, but not chemotherapy had a survival rate of 12.1.
Tumor-treating fields can be applied to the pleura or the thin lining that surrounds your lungs, either on your abdomen or chest wall. The device is small enough to be worn for up to 18 hours per day, including sleep. Patients are able to live their lives and work while undergoing treatment.
TT fields can be incorporated with conventional chemotherapy and immunotherapy, as well as other mesothelioma treatment options. Mesothelioma patients interested in TT fields should discuss this possibility with their mesothelioma specialist who will explain the eligibility requirements and anticipated benefits for the patient’s particular case.
g
Aucune réponse